Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Massachusetts Biotech Presents Catalysts Into 2024

Source: Dr. David Nierengarten


November 9, 2023 ( Newswire) Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten.

Cambridge, Massachusetts-based iTeos Therapeutics Inc. (ITOS:NASDAQ) reported Q3 2023 financial results and upcoming clinical catalysts, noted Wedbush Securities analyst Dr. David Nierengarten in a November 7 research report.

The key near-term catalysts will be Phase 2 data in 2024 for iTeos' lead asset, TIGIT inhibitor belrestotug, in combination with PD-1 inhibitor dostarlimab from GlaxoSmithKline (GSK) in NSCLC and head and neck squamous cell carcinoma (HNSCC) patients.

Per the analysts, the belrestotug-dostarlimab combo could be differentiated given prior belrestotug monotherapy data and recent positive dostarlimab results versus pembrolizumab.

Beyond NSCLC and HNSCC, belrestotug combination trials are underway in multiple myeloma, plus triplets adding experimental GSK CD96 and PVRIG inhibitors.

For A2A receptor antagonist inupadenant, iTeos is enrolling in a Phase 2 study in lung cancer and plans to start a Phase 1/2 study of inupadenant with pipeline asset EOS-984 in 2024.

The Wedbush analysts highlighted iTeos' "healthy balance sheet" funding operations through 2026 upcoming data readouts for all three clinical programs.

With shares trading below cash value, the firm sees significant upside potential and reiterates an Outperform rating with a US$33 price target.

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire

Global investors must adhere to regulations of each country. Please read privacy policy:

That's all it takes to get an article published on Investor Ideas - Learn More - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on